title: NKT cell adjuvants in therapeutic vaccines against hematological cancers.
abstract: Immune adjuvants aimed at initiating or re-activating host immunity against poorly immunogenic cancers represent a potential tool for immunotherapy. By employing the natural killer T (NKT) cell agonist α-galactosylceramide in a whole tumor cell therapeutic vaccine approach, we have achieved potent suppression of established hematological cancers upon the elicitation of innate and adaptive antitumor immunity.
authors.affiliation: Cancer Immunology Program; Peter MacCallum Cancer Centre; East Melbourne, Victoria, Australia ; The University of Queensland Diamantina Institute; Princess Alexandra Hospital; Woolloongabba, Queensland, Australia.
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Mattarollo
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
keywords: NKT cells; hematological malignancies; immune adjuvants; immunotherapy; tumor vaccine; α-galactosylceramide